Martinostat as a novel HDAC inhibitor to overcome tyrosine kinase inhibitor resistance in chronic myeloid leukemia

20251 citationsJournal Articlegold Open Access

Authors

Haeun Yang · Seoul National University

Vladimir Li · Seoul National University

Su Jung Park · Seoul National University

Sang Won Cheon · Seoul National University

Anne Lorant · Hôpital Kirchberg

Aloran Mazumder · Seoul National University

Jin‐Young Lee ·

Abstract

These findings highlight the potential of martinostat as a selective, low-toxicity HDACi that, combined with TKIs, could provide an effective strategy to overcome drug resistance in CML and improve therapeutic outcomes.

Topics & Keywords

Histone Deacetylase Inhibitors Research Chronic Myeloid Leukemia Treatments Acute Myeloid Leukemia Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Epigenetics

Volume 17, Issue 1, pp. 125-125

DOI: 10.1186/s13148-025-01921-0

Field-Weighted Citation Impact: 0.84